1 / 6

BCG Vaccine Market Focus to Boost Revenue with Massive Growth

Global BCG Vaccine Market was valued at $20,366 thousands in 2016, and is estimated to reach $28,051 thousands by 2023, growing at a CAGR of 4.6% from 2017 to 2023.

newmarketindustry
Télécharger la présentation

BCG Vaccine Market Focus to Boost Revenue with Massive Growth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BCG Vaccine Market

  2. As there is no current alternative to BCG vaccine, therefore there is an urgent need to improve the methods used for quality control of BCG. This is possible with the help of technological advancements in the field of genomics and proteomics, which can help in development of new methods for BCG testing. These advanced testing methods can ensure the safety, quality, and efficacy of BCG vaccine preparations. Get Sample Report

  3. Bacillus Calmette-Gurin (BCG) vaccine is the only vaccine currently available for prevention of tuberculosis (TB). One dose of BCG vaccine is recommended for healthy babies at birth in countries where tuberculosis is common. The major factor that contributes to the market growth are increase in incidence rate of tuberculosis in developing nations, rise in R&D activities related to vaccines, and growth in government initiatives and focus on immunization programs globally.

  4. However, side reactions of BCG vaccines on patients and shortage of vaccine supply hinder the market growth. Moreover, untapped market opportunities in developing regions are expected to provide numerous opportunities for market growth. The pediatrics segment is expected to maintain its dominant position during the analysis period, as the vaccine is administered to all the children at the time of birth. As BCG is recommended for only one dose; therefore, it is used rarely in the case of adults.

  5. Key Findings of the BCG Vaccine Market: • The pediatrics segment accounted for more than three-fourths share of the global market in 2016. • China is expected to grow at a rapid CAGR of 6.2% from 2017 to 2023. • India accounted for one-sixth of the global market in 2016. • The adults segment is expected to grow at a CAGR of 3.6% from 2017 to 2023.

  6. The major companies profiled in the report include Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation), Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institut.

More Related